Elon Musk’s brain-computer interface company Neuralink is preparing for a major expansion, announcing plans to begin high-volume production of its brain implant devices and transition to a fully automated surgical procedure by 2026. The announcement was made by Musk in a post on the social media platform X, highlighting the company’s long-term vision to scale its neurotechnology and make implantation faster, safer, and more accessible.
Neuralink’s brain implant technology is designed to help people with severe neurological conditions, including spinal cord injuries and paralysis, by enabling direct communication between the brain and external devices. The implant allows users to control digital tools using their thoughts, opening new possibilities for restoring independence and improving quality of life. According to previously shared updates, the first patient implanted with the device has successfully used it to play video games, browse the internet, post on social media, and control a laptop cursor without physical movement.
The company began human trials of its brain-computer interface in 2024 after resolving safety concerns raised by the U.S. Food and Drug Administration. The FDA had initially rejected Neuralink’s application in 2022, citing potential risks, but later approved the trials after additional safeguards were implemented. This marked a significant milestone for the company and the broader neurotechnology industry.
In September, Neuralink revealed that 12 people worldwide with severe paralysis had already received its brain implants. These individuals were reportedly using the technology to control both digital and physical tools purely through thought, demonstrating the real-world potential of brain-computer interfaces. The company has also attracted strong investor interest, securing $650 million in a funding round completed in June, further supporting its research, development, and manufacturing goals.
While Neuralink did not immediately respond to a request for comment, Musk’s statement suggests the company is moving toward large-scale deployment. If successful, high-volume production and fully automated surgical implantation could significantly accelerate adoption of brain implant technology, positioning Neuralink as a leader in the rapidly evolving field of neural interfaces and medical innovation.


Intuit Raises Full-Year Forecast After Strong Q3 Earnings Despite Stock Drop
Stellantis CEO Antonio Filosa to Reveal Turnaround Strategy Focused on U.S. Sales and China Partnerships
Samsung Union Confirms 18-Day Strike After Failed Wage Talks
Google, Blackstone Launch $5B AI Cloud Venture to Challenge Nvidia and CoreWeave
OpenAI Expands Globally with First Overseas AI Lab in Singapore
NASA and Roscosmos Chiefs Meet in Florida to Discuss Moon and ISS Cooperation
X Corp Loses Legal Battle Over Australia Child Safety Fine
Astronomers have discovered another puzzling interstellar object − this third one is big, bright and fast
SpaceX IPO Nears as Goldman Sachs Set to Lead Historic $75 Billion Offering
PDG Explores $1 Billion Sale of China Data Center Assets
Anthropic Revenue Surge Signals Strong AI Market Momentum in 2026
Neuralink Expands Brain Implant Trials with 12 Global Patients
CXMT Forecasts Record Revenue Growth as Global DRAM Prices Surge
OpenAI Eyes IPO Filing as Early as This Week Amid Rising AI Competition
Blackstone and Google Launch AI Cloud Venture, Pressuring CoreWeave and Nebius Shares 



